Abstract
In the last 12 years, data has accumulated supporting an important role for hyperglycemia in the development of diabetic nephropathy, and in the same period identification and characterization of renal glucose transporters has expanded rapidly. This new knowledge concerning glucose transporters is now being used to determine the roles they may play in diabetic kidney disease. Recent studies of renal glucose transporters have characterized their responses to diabetes, and their potential roles in the diabetic kidney. Glucose transporters have been shown to be rate-limiting for mesangial cell glucose uptake, glucose metabolism and extracellular matrix (ECM) production by these cells. Furthermore, increased renal GLUT1 has been proposed to play an important role in the development of diabetic glomerulosclerosis. Recent data suggest increased GLUT8 in podocytes may contribute to diabetic glomerular disease as well. Renal tubular glucose transporter expression is also altered in diabetes, responding to the increased need for glucose reabsorption . However, further investigation is required to determine the potential roles of these glucose transporters in the interstitial kidney disease associated with diabetes.
Keywords: Glucose transporter, GLUT, SGLT, diabetic nephropathy, mesangial cell
Current Enzyme Inhibition
Title: Glucose Transporters in Normal and Diabetic Kidneys
Volume: 2 Issue: 3
Author(s): Charles W. Heilig and Youli Wang
Affiliation:
Keywords: Glucose transporter, GLUT, SGLT, diabetic nephropathy, mesangial cell
Abstract: In the last 12 years, data has accumulated supporting an important role for hyperglycemia in the development of diabetic nephropathy, and in the same period identification and characterization of renal glucose transporters has expanded rapidly. This new knowledge concerning glucose transporters is now being used to determine the roles they may play in diabetic kidney disease. Recent studies of renal glucose transporters have characterized their responses to diabetes, and their potential roles in the diabetic kidney. Glucose transporters have been shown to be rate-limiting for mesangial cell glucose uptake, glucose metabolism and extracellular matrix (ECM) production by these cells. Furthermore, increased renal GLUT1 has been proposed to play an important role in the development of diabetic glomerulosclerosis. Recent data suggest increased GLUT8 in podocytes may contribute to diabetic glomerular disease as well. Renal tubular glucose transporter expression is also altered in diabetes, responding to the increased need for glucose reabsorption . However, further investigation is required to determine the potential roles of these glucose transporters in the interstitial kidney disease associated with diabetes.
Export Options
About this article
Cite this article as:
Heilig W. Charles and Wang Youli, Glucose Transporters in Normal and Diabetic Kidneys, Current Enzyme Inhibition 2006; 2 (3) . https://dx.doi.org/10.2174/157340806777934757
DOI https://dx.doi.org/10.2174/157340806777934757 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Coronary Risk Assessment and Management Options in Chronic Kidney Disease Patients Prior to Kidney Transplantation
Current Cardiology Reviews EDITORIAL [Hot Topic-II: PPAR Ligands and Cardiovascular Disorders: Friend or Foe (Guest Editors: Pitchai Balakumar and Gowraganahalli Jagadeesh)]
Current Molecular Pharmacology Therapeutic Application of Melatonin in the Treatment of Melanoma: A Review
Current Cancer Therapy Reviews Pharmacological Treatment of Hypertension in Pregnancy
Current Pharmaceutical Design Ezetimibe Therapy for Dyslipidemia: An Update
Current Pharmaceutical Design Use of High-Throughput Trypsin Digestion in Proteomic Studies
Current Proteomics Editorial (Should Chronic Kidney Disease be Considered as a Coronary Heart Disease Equivalent?)
Current Vascular Pharmacology Aldose Reductase in Diabetic Microvascular Complications
Current Drug Targets The Clinical Pathway for Hypertensive Patient of Local Health Unit, Hospitals and General Practitioners, the Milan Experience
Reviews on Recent Clinical Trials Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design Plastid Molecular Pharming II. Production of Biopharmaceuticals by Plastid Transformation
Mini-Reviews in Medicinal Chemistry Diagnosis of Renal Diseases Based on Machine Learning Methods Using Ultrasound Images
Current Medical Imaging A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure
Current Vascular Pharmacology Cardioprotective Effects and <i>in-silico</i> Antioxidant Mechanism of L-Ergothioneine in Experimental Type-2 Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues
Current Drug Safety Nephroangiosclerosis and Its Pharmacological Approach
Current Vascular Pharmacology Biomarkers of Protein Oxidation in Human Disease
Current Molecular Medicine Pain Management in Hematological Patients with Major Organ Dysfunctions and Comorbid Illnesses
Cardiovascular & Hematological Agents in Medicinal Chemistry Growth Arrest Specific Gene (GAS) 6 Modulates Platelet Thrombus Formation and Vascular Wall Homeostasis and Represents an Attractive Drug Target
Current Pharmaceutical Design Metabolic Syndrome X is a Low-Grade Systemic Inflammatory Condition with its Origins in the Perinatal Period
Current Nutrition & Food Science